ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 971,38
1,72%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Can Fite BioPharma Ltd (CANF)

  7. Can Fite BioPharma Ltd (CANF) Actualités

CANF Can Fite BioPharma Ltd

2,12
0,09 (4,43%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Can Fite BioPharma Ltd CANF AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,09 4,43% 2,12 01:59:56
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,03 2,00 2,27 2,09 2,03
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202413:00BWLong-term Complete Response to Can-Fite's Namodenoson in..
15/4/202413:00BWCan-Fite: Scientific Article Published by KOL Presents..
03/4/202413:00BWCan-Fite: Submits FDA with an IND Application to Conduct..
28/3/202412:00BWCan-Fite Reports 2023 Financial Results and Clinical Update
11/3/202412:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/3/202412:00BWNamodenoson Treatment for Pancreatic and Liver Cancer: Data..
28/2/202413:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202413:00BWCan-Fite Broadens its Strong Intellectual Property (IP) for..
14/2/202421:32EDGAR2Form SC 13G - Statement of acquisition of beneficial..
30/1/202413:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202413:00BWCan-Fite Expands the Out-Licensing Deal with Ewopharma to..
29/1/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/1/202413:00BWCan-Fite: Top Scientific Journal Published Positive Data..
08/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
28/12/202322:16EDGAR2Form F-3/A - Registration statement by foreign private..
20/12/202313:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202313:00BWThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular..
18/12/202313:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/12/202313:00BWCan-Fite Received FDA Positive Response to Psoriasis..
12/12/202322:15EDGAR2Form F-3 - Registration statement by foreign private issuers
04/12/202313:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202313:00BWCan-Fite’s Namodenoson for the Treatment of Pancreatic..
30/11/202313:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/11/202313:00BWCan-Fite Reports Third Quarter 2023 Financial Results and..
22/11/202322:20EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22/11/202322:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202319:53GLOBECan-Fite Announces Exercise of Warrants for Approximately..
21/11/202313:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202313:00BWCan-Fite: Complete Response and 6.9 Years Overall Survival..
01/11/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202312:00BWCan-Fite Issues Business Update: All Clinical Programs and..
30/10/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/10/202312:00BWCan Fite: Namodenoson Inhibits Pancreatic Carcinoma..
26/10/202313:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/10/202313:00BWCan-Fite to Harness Artificial Intelligence to Develop Novel..
10/10/202313:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/10/202313:00BWCan-Fite to Share its Rare Genetic Disease Lowe Syndrome..
27/9/202313:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/9/202313:00BWCan-Fite Novel Approach for the Treatment of Pancreatic..
07/9/202313:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/9/202313:00BWCan-Fite to Share with Investors Latest Oncology and Rare..
01/9/202322:16EDGAR2Form POS AM - Post-Effective amendments for registration..
01/9/202322:15EDGAR2Form F-3 - Registration statement by foreign private issuers
31/8/202313:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/8/202313:00BWCan-Fite Reports Second Quarter 2023 Financial Results &..
24/8/202313:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/8/202313:10BWCan-Fite Enters Rare Genetic Disease Field Based on..
18/8/202313:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/8/202313:00BWCan-Fite Submitted to FDA a Pediatric Plan to Allow..

Dernières Valeurs Consultées

AMEX
CANF
Can Fite BioPharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés